New developments in Sjogren's syndrome. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


New developments in Sjogren's syndrome.

Curr Opin Rheumatol. 1991 Oct;3(5):815-22. Unique Identifier : AIDSLINE MED/92088843
Moutsopoulos HM; Youinou P; School of Medicine, University of Ioannina, Greece.

Abstract: Over the past months, noteworthy contributions to our understanding of the clinical manifestations of Sjogren's syndrome have been made. Scintigraphic and echographic techniques have been refined to document xerostomia. Various systemic complications, such as nervous system involvement, pulmonary lesions, gastric and pancreatic dysfunction, and Raynaud's phenomenon have been further described. Mast cells have been shown to participate in the salivary gland infiltration, together with T lymphocytes, of which the majority are of the memory helper/inducer phenotype. Antinuclear antibodies are directed to SS-A/Ro and SS-B/La particles. Two studies have been devoted to the cloning of the DNA encoding the 52-kD component of the former, and a series of SS-B/La DNA fragments have been generated to analyze the peptides of the latter. Virologic data have been provided, particularly the detection of anti-human immunodeficiency virus type 1 p24 protein in a number of Sjogren's syndrome patients, and the discovery of a human intracisternal A-type retroviral particle in lymphoblastoid cells exposed to homogenates of salivary tissue from patients with Sjogren's syndrome.
Keywords: Autoimmunity Human HIV Infections/COMPLICATIONS *Sjogren's Syndrome/COMPLICATIONS/DIAGNOSIS/IMMUNOLOGY JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDautoimmunityhumanhivinfections/complicationsKWDsjogren'ssyndrome/complications/diagnosis/immunologyjournalarticlereviewreview,tutorial
920430
M9240922

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .